ZA9610722B - Aromatic keto-acids and their derivatives as inhibitors of matrix metalloproteinases - Google Patents

Aromatic keto-acids and their derivatives as inhibitors of matrix metalloproteinases

Info

Publication number
ZA9610722B
ZA9610722B ZA9610722A ZA9610722A ZA9610722B ZA 9610722 B ZA9610722 B ZA 9610722B ZA 9610722 A ZA9610722 A ZA 9610722A ZA 9610722 A ZA9610722 A ZA 9610722A ZA 9610722 B ZA9610722 B ZA 9610722B
Authority
ZA
South Africa
Prior art keywords
pct
inhibitors
derivatives
matrix metalloproteinases
sec
Prior art date
Application number
ZA9610722A
Other languages
English (en)
Inventor
Donald Hupe
Daniel Fred Ortwine
Andrew David White
Linda Lea Johnson
Purchase Claude Forsey Jr
Qi-Zhuang Ye
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA9610722B publication Critical patent/ZA9610722B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
ZA9610722A 1995-12-22 1996-12-19 Aromatic keto-acids and their derivatives as inhibitors of matrix metalloproteinases ZA9610722B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US948995P 1995-12-22 1995-12-22

Publications (1)

Publication Number Publication Date
ZA9610722B true ZA9610722B (en) 1997-06-27

Family

ID=21737977

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9610722A ZA9610722B (en) 1995-12-22 1996-12-19 Aromatic keto-acids and their derivatives as inhibitors of matrix metalloproteinases

Country Status (19)

Country Link
US (1) US6008220A (xx)
EP (1) EP0876343B1 (xx)
JP (1) JP2000502343A (xx)
AT (1) ATE214368T1 (xx)
AU (1) AU713174C (xx)
BG (1) BG63461B1 (xx)
BR (1) BR9612188A (xx)
CZ (1) CZ287868B6 (xx)
DE (1) DE69619865T2 (xx)
DK (1) DK0876343T3 (xx)
ES (1) ES2175155T3 (xx)
HU (1) HU222986B1 (xx)
NO (1) NO309470B1 (xx)
NZ (1) NZ323329A (xx)
PL (1) PL327494A1 (xx)
PT (1) PT876343E (xx)
SK (1) SK87598A3 (xx)
WO (1) WO1997023459A1 (xx)
ZA (1) ZA9610722B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153757A (en) * 1995-12-08 2000-11-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors and intermediates useful for their preparation
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
US5795985A (en) * 1996-03-05 1998-08-18 Ciba Specialty Chemicals Corporation Phenyl alkyl ketone substituted by cyclic amine and a process for the preparation thereof
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
EP1366765A1 (en) * 1996-12-17 2003-12-03 Warner-Lambert Company Llc Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
PT946166E (pt) 1996-12-17 2004-06-30 Warner Lambert Co Utilizacao de inibidores das metaloproteinases da matriz para tratar disturbios neurologicos e promover a cicatrizacao de feridas
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6420427B1 (en) 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CN106518845B (zh) 2011-08-30 2019-09-13 Chdi基金会股份有限公司 犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法
BR112014004845A2 (pt) 2011-08-30 2017-04-04 Chdi Foundation Inc pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
SG11201700341PA (en) 2014-07-17 2017-02-27 Chdi Foundation Inc Methods and compositions for treating hiv-related disorders
US20170327457A1 (en) * 2014-09-09 2017-11-16 Bristol-Myers Squibb Company Phenyl-(aza)cycloalkyl carboxylic acid gpr120 modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0821671T3 (da) * 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
AU741768B2 (en) * 1996-12-09 2001-12-06 Warner-Lambert Company Method for treating and preventing heart failure and ventricular dilatation
PT946166E (pt) * 1996-12-17 2004-06-30 Warner Lambert Co Utilizacao de inibidores das metaloproteinases da matriz para tratar disturbios neurologicos e promover a cicatrizacao de feridas

Also Published As

Publication number Publication date
DE69619865T2 (de) 2002-11-07
EP0876343A1 (en) 1998-11-11
CZ287868B6 (en) 2001-02-14
NO982840L (no) 1998-06-19
US6008220A (en) 1999-12-28
ATE214368T1 (de) 2002-03-15
SK87598A3 (en) 1999-04-13
BG102471A (en) 1999-08-31
NO982840D0 (no) 1998-06-19
WO1997023459A1 (en) 1997-07-03
HUP9902079A3 (en) 2000-06-28
NO309470B1 (no) 2001-02-05
DK0876343T3 (da) 2002-07-01
PL327494A1 (en) 1998-12-21
ES2175155T3 (es) 2002-11-16
NZ323329A (en) 1999-02-25
AU713174C (en) 2002-05-02
DE69619865D1 (de) 2002-04-18
HU222986B1 (hu) 2004-01-28
JP2000502343A (ja) 2000-02-29
AU713174B2 (en) 1999-11-25
AU1024997A (en) 1997-07-17
MX9803315A (es) 1998-09-30
BR9612188A (pt) 1999-07-13
BG63461B1 (bg) 2002-02-28
PT876343E (pt) 2002-08-30
HUP9902079A2 (hu) 1999-10-28
EP0876343B1 (en) 2002-03-13
CZ195298A3 (cs) 1998-09-16

Similar Documents

Publication Publication Date Title
IL123901A (en) Sulfonamide inhibitors of matrix metalloproteinases and pharmaceutical compositions comprising them
ZA9610722B (en) Aromatic keto-acids and their derivatives as inhibitors of matrix metalloproteinases
NO972980L (no) Anvendelse av nebivolol som et anti-aterogent middel
NZ509439A (en) Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
NO964486D0 (no) Anvendelse av visse metanbisfosfonsyrederivater for å forhindre lösning av protese og protesemigrering
MY114926A (en) N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists
BR9712794A (pt) Compostos para e um método de inibição de metaloproteinases matriciais
ZA964508B (en) Tricyclic inhibitors of matrix metalloproteinases
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
CA2233560A1 (en) Sulfonamide inhibitors of matrix metalloproteinases
WO1998038985A3 (en) Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases
ATE190845T1 (de) Rektale flunisolid-zubereitung zur behandlung entzündlicher darmerkrankungen
UY24693A1 (es) Ácidos bifenil butíricos y sus derivados como inhibidores de metaloproteinasas de matriz